$CDNA
CareDx, Inc.

2020 Q1 Form 10-Q Financial Statement

#000121723420000057 Filed on April 30, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $38.38M $25.98M
YoY Change 47.72% 84.89%
Cost Of Revenue $12.39M $9.733M
YoY Change 27.32% 136.7%
Gross Profit $25.99M $16.25M
YoY Change 59.94% 63.45%
Gross Profit Margin 67.71% 62.54%
Selling, General & Admin $21.73M $16.03M
YoY Change 35.52% 70.69%
% of Gross Profit 83.6% 98.66%
Research & Development $10.01M $5.614M
YoY Change 78.36% 66.69%
% of Gross Profit 38.53% 34.55%
Depreciation & Amortization $1.619M $1.160M
YoY Change 39.57% 11.54%
% of Gross Profit 6.23% 7.14%
Operating Expenses $44.13M $21.65M
YoY Change 103.89% 12.22%
Operating Profit -$5.751M -$5.396M
YoY Change 6.58% 3.08%
Interest Expense $96.00K $342.0K
YoY Change -71.93% -112.69%
% of Operating Profit
Other Income/Expense, Net -$372.0K -$2.741M
YoY Change -86.43% -34.47%
Pretax Income -$6.123M -$8.137M
YoY Change -24.75% -13.6%
Income Tax -$300.0K -$600.0K
% Of Pretax Income
Net Earnings -$5.823M -$7.531M
YoY Change -22.68% -16.03%
Net Earnings / Revenue -15.17% -28.99%
Basic Earnings Per Share -$0.14 -$0.18
Diluted Earnings Per Share -$0.14 -$0.18
COMMON SHARES
Basic Shares Outstanding 42.82M shares 41.61M shares
Diluted Shares Outstanding 42.82M shares 41.61M shares

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.20M $57.40M
YoY Change -43.9% 206.95%
Cash & Equivalents $32.19M $57.62M
Short-Term Investments
Other Short-Term Assets $4.100M $2.400M
YoY Change 70.83% -4.0%
Inventory $6.947M $5.200M
Prepaid Expenses
Receivables $22.84M $12.50M
Other Receivables $0.00 $0.00
Total Short-Term Assets $66.07M $77.60M
YoY Change -14.86% 137.31%
LONG-TERM ASSETS
Property, Plant & Equipment $5.501M $6.300M
YoY Change -12.68% 200.0%
Goodwill $23.86M
YoY Change
Intangibles $43.11M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.000M $200.0K
YoY Change 400.0% 0.0%
Total Long-Term Assets $90.72M $50.26M
YoY Change 80.5% 8.55%
TOTAL ASSETS
Total Short-Term Assets $66.07M $77.60M
Total Long-Term Assets $90.72M $50.26M
Total Assets $156.8M $127.9M
YoY Change 22.62% 61.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.621M $3.859M
YoY Change 71.57% -10.26%
Accrued Expenses $10.10M $9.300M
YoY Change 8.6% 22.37%
Deferred Revenue $3.482M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K $0.00
YoY Change -100.0%
Total Short-Term Liabilities $28.32M $16.37M
YoY Change 73.02% 22.16%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.743M $2.775M
YoY Change -37.19% -84.58%
Total Long-Term Liabilities $1.743M $2.775M
YoY Change -37.19% -89.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.32M $16.37M
Total Long-Term Liabilities $1.743M $2.775M
Total Liabilities $55.40M $32.24M
YoY Change 71.85% -29.3%
SHAREHOLDERS EQUITY
Retained Earnings -$339.6M -$319.4M
YoY Change 6.33%
Common Stock $447.9M $420.0M
YoY Change 6.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $101.4M $95.62M
YoY Change
Total Liabilities & Shareholders Equity $156.8M $127.9M
YoY Change 22.62% 61.85%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$5.823M -$7.531M
YoY Change -22.68% -16.03%
Depreciation, Depletion And Amortization $1.619M $1.160M
YoY Change 39.57% 11.54%
Cash From Operating Activities -$3.055M -$5.867M
YoY Change -47.93% 29.86%
INVESTING ACTIVITIES
Capital Expenditures $1.704M $543.0K
YoY Change 213.81% 775.81%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$1.704M -$543.0K
YoY Change 213.81% -27.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$735.0K -$688.0K
YoY Change 6.83% -70.32%
NET CHANGE
Cash From Operating Activities -$3.055M -$5.867M
Cash From Investing Activities -$1.704M -$543.0K
Cash From Financing Activities -$735.0K -$688.0K
Net Change In Cash -$6.046M -$7.185M
YoY Change -15.85% -5.12%
FREE CASH FLOW
Cash From Operating Activities -$3.055M -$5.867M
Capital Expenditures $1.704M $543.0K
Free Cash Flow -$4.759M -$6.410M
YoY Change -25.76% 39.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001217234
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P8Y2M
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
001-36536
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
CAREDX, INC.
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3316839
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1 Tower Place
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2020Q1 dei City Area Code
CityAreaCode
415
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
287-2300
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020Q1 dei Trading Symbol
TradingSymbol
CDNA
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43784236 shares
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32191000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38223000 USD
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22841000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24057000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
6947000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
6014000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4089000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3628000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
66068000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
71922000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5501000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4430000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17004000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4730000 USD
CY2020Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
43112000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
45541000 USD
CY2020Q1 us-gaap Goodwill
Goodwill
23857000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
23857000 USD
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
242000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
256000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1000000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1000000 USD
CY2020Q1 us-gaap Assets
Assets
156784000 USD
CY2019Q4 us-gaap Assets
Assets
151736000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6621000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5506000 USD
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6127000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12484000 USD
CY2020Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15576000 USD
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16838000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
28324000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34828000 USD
CY2020Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1502000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1973000 USD
CY2020Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1017000 USD
CY2019Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6607000 USD
CY2020Q1 cdna Deferred Payments For Intangible Assets Noncurrent
DeferredPaymentsForIntangibleAssetsNoncurrent
5311000 USD
CY2019Q4 cdna Deferred Payments For Intangible Assets Noncurrent
DeferredPaymentsForIntangibleAssetsNoncurrent
5207000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17503000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2370000 USD
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1743000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1751000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
55400000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
52736000 USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43019547 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43019547 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42498430 shares
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
447888000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
437976000 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
42000 USD
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42498430 shares
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
42000 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6910000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5205000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-339636000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-333813000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
101384000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
99000000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
156784000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
151736000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38380000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25982000 USD
CY2020Q1 us-gaap Cost Of Revenue
CostOfRevenue
12392000 USD
CY2019Q1 us-gaap Cost Of Revenue
CostOfRevenue
9733000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
25988000 USD
CY2019Q1 us-gaap Gross Profit
GrossProfit
16249000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10013000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5614000 USD
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11723000 USD
CY2019Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6925000 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10003000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9106000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
31739000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
21645000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5751000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5396000 USD
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
96000 USD
CY2019Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
342000 USD
CY2020Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-405000 USD
CY2019Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3009000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-63000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-74000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-372000 USD
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2741000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6123000 USD
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8137000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-300000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-606000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5823000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7531000 USD
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42823427 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41611399 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42823427 shares
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41611399 shares
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5823000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7531000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1705000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-724000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7528000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8255000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
99000000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
699000 USD
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-1507000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
66000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
155000 USD
CY2020Q1 cdna Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value
IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue
6299000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4200000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1705000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5823000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
101384000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
95928000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
341000 USD
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2378000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
51000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1365000 USD
CY2019Q1 cdna Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value
IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue
2569000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6001000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-724000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7531000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
95622000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5823000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7531000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4259000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6053000 USD
CY2020Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-405000 USD
CY2019Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3009000 USD
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1619000 USD
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1161000 USD
CY2020Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
612000 USD
CY2019Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
372000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
190000 USD
CY2019Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2346000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2782000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1343000 USD
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
372000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
545000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
541000 USD
CY2020Q1 cdna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-344000 USD
CY2019Q1 cdna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-475000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1757000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-4249000 USD
CY2020Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
48000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-449000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-5914000 USD
CY2019Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
202000 USD
CY2020Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
322000 USD
CY2019Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
265000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3055000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5867000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1704000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
543000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1704000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-543000 USD
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
358000 USD
CY2019Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
341000 USD
CY2020Q1 cdna Taxes Paid Related To Net Share Settlement Of Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits
1507000 USD
CY2019Q1 cdna Taxes Paid Related To Net Share Settlement Of Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits
2378000 USD
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
304000 USD
CY2019Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
78000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
155000 USD
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1365000 USD
CY2020Q1 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
45000 USD
CY2019Q1 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
42000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-735000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-688000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-552000 USD
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-87000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6046000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7185000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38479000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64808000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32433000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57623000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32191000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38223000 USD
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
242000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
256000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32433000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38479000 USD
CY2018Q1 cdna Number Of Renal Transplant Patients
NumberOfRenalTransplantPatients
1500 patient
CY2020Q1 cdna Number Of Transplant Centers Offering Remo Tra C
NumberOfTransplantCentersOfferingRemoTraC
140 center
CY2020Q1 cdna Number Of Patients Enrolled In Remo Tra C
NumberOfPatientsEnrolledInRemoTraC
2000 patient
CY2020Q1 cdna Number Of Mobile Phlebotomists
NumberOfMobilePhlebotomists
10000 phlebotomist
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-339600000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32200000 USD
CY2020Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Reclassifications and Changes in Presentation</span></div><div style="margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain prior period amounts have been reclassified to conform with the current period presentation, including: (i) combined presentation of cost of testing services, cost of product, and cost of digital, and (ii) separate presentation of gross profit. These reclassifications had no effect on the reported results of operations.</span></div>
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of digital revenue performance obligations; accrued expenses for clinical studies; inventory valuation; the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired); the fair value of contingent consideration recorded in connection with a business combination; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div>
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:10pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020 and 2019, approximately 53% and 55% respectively, of total revenue was derived from Medicare. No other payers or customers represented more than 10% of total revenue for these periods.</span></div><div style="margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020 and December 31, 2019, approximately 20% and 36%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable on either March 31, 2020 or December 31, 2019.</span></div>
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5823000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7531000 USD
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42823427 shares
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41611399 shares
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4396880 shares
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4101523 shares
CY2019Q2 us-gaap Goodwill
Goodwill
10200000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
23857000 USD
CY2020Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0 USD
CY2020Q1 us-gaap Goodwill
Goodwill
23857000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
57713000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11868000 USD
CY2020Q1 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
4836000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
41009000 USD
CY2020Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
59816000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11868000 USD
CY2020Q1 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
4836000 USD
CY2020Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
43112000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
57713000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10719000 USD
CY2019Q4 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
3556000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
43438000 USD
CY2019Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
59816000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10719000 USD
CY2019Q4 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
3556000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
45541000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000 USD
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3389000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4290000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4273000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
4273000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
4273000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
20511000 USD
CY2020Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
41009000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3686000 USD
CY2020Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1347000 USD
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1236000 USD
CY2020Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1685000 USD
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1189000 USD
CY2020Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3915000 USD
CY2019Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3589000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
6947000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
6014000 USD
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3482000 USD
CY2020Q1 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
4084000 USD
CY2019Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
3068000 USD
CY2020Q1 cdna Deferred Payments For Intangible Assets
DeferredPaymentsForIntangibleAssets
2038000 USD
CY2019Q4 cdna Deferred Payments For Intangible Assets
DeferredPaymentsForIntangibleAssets
2098000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1570000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3017000 USD
CY2020Q1 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
884000 USD
CY2019Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
835000 USD
CY2020Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
562000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
547000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
970000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
810000 USD
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
609000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
766000 USD
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1377000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2011000 USD
CY2020Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15576000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1600000 USD
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16838000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17000000.0 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17500000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1119000 USD
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
435000 USD
CY2020Q1 cdna Finance Lease Cost
FinanceLeaseCost
53000 USD
CY2019Q1 cdna Finance Lease Cost
FinanceLeaseCost
56000 USD
CY2020Q1 us-gaap Lease Cost
LeaseCost
1172000 USD
CY2019Q1 us-gaap Lease Cost
LeaseCost
491000 USD
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y25D
CY2020Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y29D
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105
CY2020Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.065
CY2020Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1200000 USD
CY2019Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
157000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2514000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
71000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3511000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3963000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2811000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
228000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2909000 USD
CY2020Q1 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
13267000 USD
CY2020Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000 USD
CY2019Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
28975000 USD
CY2014Q2 cdna Number Of Milestone Payments
NumberOfMilestonePayments
6 milestone_payment
CY2020Q1 cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
272000 shares
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
300000 USD
CY2020Q1 cdna Number Of Warrants Exercised Cashless Basis
NumberOfWarrantsExercisedCashlessBasis
34000 shares
CY2020Q1 cdna Stock Issued During Period Shares Cashless Warrants Exercises In Period
StockIssuedDuringPeriodSharesCashlessWarrantsExercisesInPeriod
24000 shares
CY2019Q1 cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
70000 shares
CY2019Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
100000 USD
CY2019Q1 cdna Estimated Fair Value Of Warrant Liability Remeasurement Income Expense
EstimatedFairValueOfWarrantLiabilityRemeasurementIncomeExpense
-500000 USD
CY2019Q1 cdna Number Of Warrants Exercised Cashless Basis
NumberOfWarrantsExercisedCashlessBasis
56000 shares
CY2019Q1 cdna Stock Issued During Period Shares Cashless Warrants Exercises In Period
StockIssuedDuringPeriodSharesCashlessWarrantsExercisesInPeriod
25000 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
504775 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2609848 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.47
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1699549 shares
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services
ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices
3091 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
294481 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
332400 shares
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Including Prior Period Shares Adjustment
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossIncludingPriorPeriodSharesAdjustment
334900 shares
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.00
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
44861 shares
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.46
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans
67477 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
41725 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
43762 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
43762 shares
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
25.75
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
10263 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
10263 shares
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.76
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1737579 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2845862 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.46
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
700000 USD
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6000000.0 USD
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
13952000000 USD
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
1144000 shares
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
10.72
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
P6Y7M9D
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
1576000 shares
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
21.96
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P8Y10M24D
CY2020Q1 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
5311000000 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2720000 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
19263000000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38380000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4259000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6053000 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-300000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-600000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-300000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25982000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5501000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4430000 USD

Files In Submission

Name View Source Status
0001217234-20-000057-index-headers.html Edgar Link pending
0001217234-20-000057-index.html Edgar Link pending
0001217234-20-000057.txt Edgar Link pending
0001217234-20-000057-xbrl.zip Edgar Link pending
caredx-exhibit101xexec.htm Edgar Link pending
caredx-exhibit102xexec.htm Edgar Link pending
cdna-20200331.htm Edgar Link pending
cdna-20200331.xsd Edgar Link pending
cdna-20200331x10qxexx3.htm Edgar Link pending
cdna-20200331x10qxexx31.htm Edgar Link pending
cdna-20200331x10qxexx32.htm Edgar Link pending
cdna-20200331_cal.xml Edgar Link unprocessable
cdna-20200331_def.xml Edgar Link unprocessable
cdna-20200331_htm.xml Edgar Link completed
cdna-20200331_lab.xml Edgar Link unprocessable
cdna-20200331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending